<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553094</url>
  </required_header>
  <id_info>
    <org_study_id>2020-01</org_study_id>
    <nct_id>NCT04553094</nct_id>
  </id_info>
  <brief_title>Effects of Personalized Training at Home Combining Endurance and Resistance in Patients Suffering From Marfan Syndrome</brief_title>
  <acronym>MARF'HOME</acronym>
  <official_title>Evaluation of the Effects of Personalized Training at Home Combining Endurance and Resistance in Patients Suffering From Marfan Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marfan syndrome (MS) is an autosomal dominant genetic disorder caused by a mutation in the&#xD;
      fibrillin-1 gene (FBN1) encoding the protein fibrillin-1. Fibrillin is the main component of&#xD;
      microfibrils, elements found in all of the body's tissues, and this pathology is&#xD;
      characterized by the multitude of its clinical manifestations. These patients may develop&#xD;
      aneurysms in the aortic root and one of the main factors of morbidity in patients with MS is&#xD;
      aortic dissection. Prevention mainly involves preventive aortic surgery. However, the&#xD;
      repercussions are global and can affect the functioning of other tissues such as skeletal&#xD;
      muscle tissue, bone tissue, lung tissue and the eyes. The association of skeletal (scoliosis,&#xD;
      hyperlaxity), muscular and ocular disorders is clearly associated with an impairment in the&#xD;
      quality of life. These disorders are associated with pain and disability which affect&#xD;
      professional activity, leisure and family life.&#xD;
&#xD;
      Physical activity could represent a relevant alternative for these patients. A recent animal&#xD;
      study suggests that moderate training is beneficial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to show that the quality of life of patients with Marfan syndrome can&#xD;
      be improved by personalized training at home. The goal is to be able to offer new non-drug&#xD;
      management based on physical activity to these patients.&#xD;
&#xD;
      Improved quality of life; Improvement of muscle strength by a muscle strengthening protocol;&#xD;
      Improvement of cardiovascular function parameters. Regular coaching throughout the study.&#xD;
&#xD;
        1. / Assessment of muscular capacities&#xD;
&#xD;
        2. / Assessment of cardiovascular and respiratory capacities&#xD;
&#xD;
        3. / Response to psychometric questionnaires&#xD;
&#xD;
        4. / Participation in a training circuit (training protocol)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 groups of physical training intervention compared with control group</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life assessment: questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed with Medical Outcome Study Short Form 36 questionnaire, a scale scored on a 0 to 100 range so that the lowest is the worth condition and highest is the best condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain assessment: Fibromyalgia Rapid Screening Tool</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed with Fibromyalgia Rapid Screening Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-perception assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Assessed with Physical Self Inventory questionnaire, a scale scoring 25 items rated on a 6-point scale ranging from 1 (Not at all) to 6 (Entirely) and assessing 6 dimensions (global self-worth (10-50), physical self-worth (10-50), physical condition (10-50), sport competence (10-40), physical attractiveness (10-30), and physical strength (10-30)) of the physical self-conception.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic diameter</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of the aortic diameter (in millimeter) in echocardiography, safety cardiovascular parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of the systolic and diastolic blood pressures (in Millimeter of mercury) during exercise, monitoring of physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of heart rate (Beats per minute) during exercise, monitoring of physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygen consumption</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of oxygen consumption (in liter) during exercise, monitoring of physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal voluntary contraction</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of maximal voluntary contraction (in Newtons) during exercise, monitoring of physiological parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of Left Ventricular Ejection Fraction (in percentage) at rest, monitoring of cardiovascular parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global longitudinal strain (GLS)</measure>
    <time_frame>3 months</time_frame>
    <description>Evolution of GLS (in percentage) at rest, monitoring of cardiovascular parameters</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No physical training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endurance training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Muscle building training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Training combining endurance + muscle building</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Endurance training</intervention_name>
    <description>Aerobic circuit training</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle building training</intervention_name>
    <description>Muscle strengthening circuit training</description>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with Marfan syndrome and followed up at Bichat Claude Bernard hospital, Paris.&#xD;
             Marfan syndrome should be diagnosed according to the Ghent nosology revised in 2010&#xD;
&#xD;
          -  Patient taking protective treatment for the aorta (beta blocker, calcium channel&#xD;
             blocker, ACE inhibitor, angiotensin II receptor antagonist).&#xD;
&#xD;
          -  Valid patient, able to return to consultation and carry out functional assessments and&#xD;
             personalized physical training at home.&#xD;
&#xD;
          -  Patients operated prophylactically on the ascending aorta may be included at a&#xD;
             distance &gt; 6 months from their surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial pathology other than Marfan syndrome.&#xD;
&#xD;
          -  Thoracic aorta dissection.&#xD;
&#xD;
          -  Aortic diameter &gt; 45 millimeters.&#xD;
&#xD;
          -  Uncontrolled high blood pressure at rest (systolic blood pressure &gt; 140 Millimeter of&#xD;
             mercury and diastolic blood pressure &gt; 90 Millimeter of mercury)&#xD;
&#xD;
          -  Increase in systolic blood pressure &gt; 160 Millimeter of mercury during exercise.&#xD;
&#xD;
          -  Pregnancy at the time of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume JONDEAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Bichat - Claude Bernard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume JONDEAU, MD</last_name>
    <phone>+33 1 40 25 68 11</phone>
    <email>guillaume.jondeau@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tessa BERGOT</last_name>
    <phone>+33 1 44 90 70 33</phone>
    <email>tessa.bergot@sfcardio.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume JONDEAU, MD</last_name>
      <phone>+33 1 40 25 68 11</phone>
      <email>guillaume.jondeau@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Physical training</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

